What is the benefit of attending? \;To learn how to evaluate the duration of protection of COVID -1
9 vaccines and about the performance of blinded and unblinded crossover de
signs in estimating long-term vaccine efficacy.
\nOverview
\n
Large-scale deployment of safe and durably effective vaccines can curta
il the COVID-19 pandemic. The COVID-19 vaccines currently in use were appr
oved on the basis of efficacy and safety data from phase 3 trials with a m
edian follow-up time of only about two months. Because of crossover\, the
phase 3 trials provided little information about the efficacy of these vac
cines beyond 6 months. Typically\, estimates of vaccine efficacy over broa
d time intervals are reported\, which are not informative about the level
of waning at the end of the observation period. Observational studies can
potentially provide information about long-term vaccine effectiveness\, bu
t they are more difficult to be analysed. In this talk\, I will discuss ho
w to properly measure and estimate vaccine efficacy/effectiveness as a fun
ction of time elapsed since vaccination while properly accounting for chan
ging transmission rates over calendar time. I will present results on the
long-term effectiveness of the Pfizer\, Moderna\, and Janssen vaccines aga
inst Covid-19\, hospitalisation\, and death in the United States.
\nRegistration
\nYou can now register for this event. This event is&
nbsp\;free of charge \;to both Members and Non Members of PSI.
\n
To register your place\, please click here.
\nSpeaker Deta
ils
\n\n\n \n \n | \n Speaker \n | \n \n Abstract \n
| \n
\n \n | \n  <
br />\n Prof. Dan-Yu Lin
\n | \n \n Large-scale deploym
ent of safe and durably effective vaccines can curtail the COVID-19 pandem
ic. However\, the high vaccine efficacy reported by ongoing phase 3 placeb
o-controlled clinical trials is based on a median follow-up time of only a
bout two months and thus does not pertain to long-term efficacy. To evalua
te the duration of protection while allowing trial participants timely acc
ess to efficacious vaccine\, investigators can sequentially cross particip
ants over from the placebo arm to the vaccine arm. Here\, we show how to e
stimate potentially time-varying placebo-controlled vaccine efficacy in th
is type of staggered vaccination of participants. In addition\, we compare
the performance of blinded and unblinded crossover designs in estimating
long-term vaccine efficacy.
\n \n
\n \n\n \;
END:VEVENT
END:VCALENDAR